{"id":36493,"date":"2010-05-05T00:00:00","date_gmt":"2010-05-05T05:00:00","guid":{"rendered":"https:\/\/www.unmc.edu\/newsroom\/2010\/05\/05\/unemed-eli-lilly-agreement-lets-unmc-participate-in-drug-discovery-program\/"},"modified":"2010-05-05T00:00:00","modified_gmt":"2010-05-05T05:00:00","slug":"unemed-eli-lilly-agreement-lets-unmc-participate-in-drug-discovery-program","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/newsroom\/2010\/05\/05\/unemed-eli-lilly-agreement-lets-unmc-participate-in-drug-discovery-program\/","title":{"rendered":"UNeMed\/Eli Lilly agreement lets UNMC participate in drug-discovery program"},"content":{"rendered":"

\"pictureUNMC is now a registered participant for Eli Lilly and Company’s new Phenotypic Drug Discovery (PD2) program. <\/p>\n

Eli Lilly — one of the world’s largest pharmaceutical companies — has launched the initiative to identify new molecules that display activity in relevant disease models and that can serve as a foundation for the development of research collaborations between the company and external researchers for the development of new therapies.<\/p>\n

The program lets UNMC researchers submit potential therapeutic compounds for phenotypic drug screening. Researchers can submit compound structures by completing a New Invention Notification (NIN) through the UNeMed office. NIN forms are available online at www.unemed.com<\/a>. <\/p>\n


\n
\n

\n
\n
\n
<\/p>\n

\n
\n
\nMore online
\n<\/B>
\n
<\/p>\n

\n
\nSee more about the program online<\/a>.
\n<\/P>
\n<\/FONT>
\n<\/TD>
\n<\/TR>
\n<\/TABLE>
\n<\/TD>
\n<\/TR>
\n<\/TABLE>The NIN will then be reviewed by the UNeMed staff and, if approved, the researcher will receive an affiliation code to submit the compound(s) on line to Eli Lilly and Company.<\/p>\n

If selected by Eli Lilly, the compounds will be screened for activity in five phenotypic assay modules:
\n